Surveillance of Acute Leukemia by Multiparameter Flow Cytometry

  • J. Drach
  • H. Glassl
  • C. Gattringer
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)


The standard definition of remission in acute leukemia is the presence of less than 5% bone marrow blasts. However, even a much lower number of leukemic cells, referred to as “minimal residual disease” (MRD), may be associated with immediate relapse. Detection of MRD by means of immunocytological criteria is mainly hampered by the fact that no truly leukemic-specific antigen has been identified as yet. Thus, it is difficult to distinguish reliably between normal and leukemic blast cells, in particular when signs of bone marrow regeneration are present. In this study we attempted to overcome these obstacles by use of maker combinations and flow cytometric multiparameter analysis. We tried to explore to what extent acute leukemias could be monitored by this strategy and whether this approach is sensitive enough to predict relapse at an early stage.


Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Acute Leukemia Minimal Residual Disease Bone Marrow Blast 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Drach J, Gattringer C, Huber H (1991) Combined flow cytometric assessment of cell surface antigens and nuclear TdT for the detection of minimal residual disease in acute leukemia. Br J Haematol 77: 37–42PubMedCrossRefGoogle Scholar
  2. 2.
    Drach J, Gattringer C, Huber H (1991) Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol 83: 418–411PubMedCrossRefGoogle Scholar
  3. 3.
    Campana D, Coustan-Smith E, Janossy G (1990) The immunologic detection of residual disease in acute leukemia. Blood 76: 163–171PubMedGoogle Scholar
  4. 4.
    Yamada M, Wassermann R, Lange B, Reichard BA, Womer RB, Rovera G (1990) Minimal residual disease in childhood B-lineage lymphoblastic leukemia. N. Engl J Med 323: 448–455PubMedCrossRefGoogle Scholar
  5. 5.
    Yokota S, Hansen-Hagge TE, Ludwig WD, Reiter A, Raghavachar A, Kleihauer E, Bartram CR (1991) Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77: 331–339PubMedGoogle Scholar
  6. 6.
    Smith RG, Kitchens RL (1989) Phenotypic heterogeneity of TdT positive cells in the blood and bone marrow: implications for surveillance of residual leukemia. Blood 74: 312–319PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. Drach
    • 1
  • H. Glassl
    • 1
  • C. Gattringer
    • 1
  1. 1.Division of Hematology and Oncology, Department of Internal MedicineUniversity of InnsbruckInnsbruckAustria

Personalised recommendations